PT-141 and Cardiovascular Research: Melanocortin Receptor Biology, Autonomic Regulation and Vascular Mechanisms UK 2026

This article is intended for research and educational purposes only. PT-141 (Bremelanotide) is a Research Use Only (RUO) compound supplied for laboratory investigation. It is not approved for human use, is not a medicine, and must not be administered to humans or animals outside of licenced research settings.

Introduction: Melanocortin Receptors and Cardiovascular Relevance

PT-141 (Bremelanotide; cyclic heptapeptide Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH) is a non-selective melanocortin receptor agonist with nanomolar affinity at MC1R, MC3R, MC4R, and MC5R. Its primary research application involves sexual function and arousal neurobiology through central MC4R hypothalamic circuits. However, melanocortin receptors — particularly MC1R (haematopoietic cells, melanocytes, vascular endothelium), MC3R (cardiovascular regulation, central autonomic circuits), and MC4R (cardiovascular autonomic control, energy balance) — have well-characterised cardiovascular biology that makes PT-141 a research tool for studying melanocortin-cardiovascular interactions distinct from its reproductive biology.

The cardiovascular effects of melanocortin receptor activation represent an important pharmacological consideration in PT-141 research — transient blood pressure elevation observed in early human studies was attributed to peripheral vasoconstriction through MC1R and possibly central autonomic effects through MC4R in the nucleus tractus solitarius (NTS). This post reviews the mechanistic basis for PT-141 cardiovascular research across autonomic regulation, vascular biology, cardiac protection, and inflammatory cardiovascular endpoints.

Melanocortin Receptor Expression in Cardiovascular Tissue

MC1R is expressed on vascular endothelial cells, vascular smooth muscle cells (VSMC), monocytes/macrophages, and cardiac fibroblasts — confirmed by RT-PCR, immunohistochemistry, and radioligand binding with [¹²⁵I]-NDP-α-MSH in isolated vessel preparations and cardiac tissue. MC1R-Gs-cAMP-PKA signalling in endothelial cells produces eNOS Ser-1177 phosphorylation through PKA-mediated activation, generating NO and promoting vasodilation — the opposite of the pressor effect observed with systemic MC agonist injection, suggesting that central autonomic effects dominate over peripheral vascular effects in intact animals.

MC3R is expressed in central autonomic circuits (NTS, dorsal motor nucleus of vagus, rostral ventrolateral medulla RVLM), in hypothalamic paraventricular nucleus (PVN), and in cardiac tissue (low expression; RT-PCR detectable). MC3R-Gs-cAMP signalling in RVLM neurons modulates sympathetic outflow to the heart and vasculature — the primary mechanism for melanocortin-mediated cardiovascular autonomic effects. MC4R expression is established in NTS, RVLM, and dorsal motor vagal nucleus, where MC4R activation increases sympathetic tone and reduces parasympathetic (vagal) activity — producing tachycardia, hypertension, and reduced heart rate variability (HRV).

Confirming which MC receptor subtype mediates specific PT-141 cardiovascular effects requires subtype-selective tools: MC3R-selective agonist γ-MSH and MC3R-selective antagonist SHU9119 (at appropriate doses); MC4R-selective agonist THIQ and selective antagonist HS024 or JKC-363; and MC1R-selective agonist BMS-470539. Comparing PT-141 (non-selective) cardiovascular effects to subtype-selective agonists establishes the receptor pharmacology landscape for each cardiovascular endpoint.

Autonomic Cardiovascular Regulation: Blood Pressure and Heart Rate

Melanocortin system activation produces blood pressure and heart rate changes through central autonomic modulation. MC4R activation in the NTS and RVLM increases sympathetic efferent firing to the heart (raising HR and contractility) and to resistance vessels (raising peripheral vascular resistance and BP), while reducing vagal tone (reducing HRV, reducing the baroreflex sensitivity). These cardiovascular autonomic effects are studied using telemetric implants (PhysioTel TA11-PA-C40 in rats; DSI PA-C10 in mice) providing 24h continuous BP, HR, and locomotor activity recording in freely moving animals.

PT-141 dose-response cardiovascular telemetry in rats: single i.v. or s.c. administration at 0.01–1mg/kg produces a dose-dependent rise in MAP (maximum +15–30 mmHg at 1mg/kg s.c.) with onset at 15–30 minutes and duration 1–3 hours, accompanied by tachycardia (+30–60 bpm) and reduced locomotor activity (sedation-like response). These cardiovascular effects are partially blocked by HS024 (MC4R antagonist; 0.1mg/kg i.c.v.) and by α-adrenergic blockade (prazosin 1mg/kg i.p. pre-treatment), but not by propranolol (β-adrenergic; confirming that the HR increase involves cardiac sympathetic activation rather than vagal withdrawal alone).

Baroreflex sensitivity (BRS) — the reflex HR change per unit MAP change — is assessed by the sequence method (spontaneous BP-HR fluctuation correlation; BRS in ms/mmHg) or pharmacological method (phenylephrine i.v. dose-response: MAP rise → HR fall; Oxford method). PT-141 reduces BRS consistent with MC4R-mediated NTS modulation suppressing baroreflex gain — a potentially significant cardiovascular autonomic effect in the context of pre-existing hypertension research models.

Cardiac Ischaemia-Reperfusion Protection: MC3R and Cytoprotection

MC3R in cardiac tissue has been implicated in cardioprotective signalling through preclinical I/R research. The mechanism proposed involves MC3R-Gs-cAMP-PKA-CREB signalling in cardiomyocytes that elevates Bcl-2:Bax ratio (anti-apoptotic), reduces caspase-3 and caspase-9 cleavage, and activates NRF2-HO-1 antioxidant pathways that attenuate I/R-induced oxidative cardiomyocyte death. Alpha-MSH (the non-selective endogenous MC agonist) reduces infarct size in Langendorff isolated heart I/R models and in in vivo LAD ligation models — effects partially reproduced by PT-141.

PT-141 in Langendorff isolated heart I/R research: hearts are perfused at 37°C with Krebs-Henseleit buffer (K-H; 118mM NaCl, 4.8mM KCl, 1.25mM CaCl₂, 25mM NaHCO₃, 1.2mM KH₂PO₄, 1.2mM MgSO₄, 11mM glucose; 95% O₂/5% CO₂). After 20-minute equilibration, global ischaemia is induced for 30 minutes (stop perfusion, 37°C) followed by 60-minute reperfusion. PT-141 (10–100nM in perfusate) is administered either as pre-treatment (5 minutes before ischaemia) or as post-conditioning (first 5 minutes of reperfusion). Primary endpoints: LVDP (mmHg), HR, coronary flow rate (mL/min), LDH release in coronary effluent (IU/L) at reperfusion 15, 30, 60 minutes, and TTC staining infarct size at endpoint (% of LV).

In vivo cardiac I/R (LAD ligation 30 minutes + reperfusion 24 hours in Sprague-Dawley rat): troponin I (cardiac-specific; ELISA) at 4h and 24h post-reperfusion; echocardiography (LVEF, LVEDV, LVESV) at 24h; histological infarct area (TTC-stained ex vivo LV slices 2mm; percentage LV infarcted) provide the in vivo cardioprotection endpoint panel. Mechanistic western blot endpoints on cardiac lysate include: Akt Ser-473, ERK1/2 Thr-202/Tyr-204, eNOS Ser-1177 (RISK pathway), GSK-3β Ser-9, cytochrome c (mitochondrial vs cytosolic fractionation), caspase-3 p17, and NLRP3-ASC-caspase-1 inflammasome activation at 15 and 60 minutes post-reperfusion.

Anti-Inflammatory Cardiovascular Biology: Melanocortin Receptor Activation in Macrophages and Endothelium

MC1R on macrophages and vascular endothelium drives anti-inflammatory signalling through Gs-cAMP-PKA-mediated NF-κB inhibition (PKA phosphorylates IκBα at Ser-32, preventing ubiquitination and proteasomal degradation, thereby maintaining IκBα inhibitory activity on NF-κB) and through IL-10 induction, POMC-derived peptide interactions, and Wnt/β-catenin anti-inflammatory crosstalk. These anti-inflammatory melanocortin actions have been most extensively characterised in inflammatory bowel disease, arthritis, and sepsis models, but cardiovascular-relevant inflammatory endpoints (monocyte adhesion, endothelial activation, macrophage foam cell formation) are directly translatable.

In TNF-α-stimulated HUVEC (10ng/mL TNF-α, 4h; or IL-1β 10ng/mL), PT-141 at 10–100nM pre-treatment (1h before cytokine) reduces: VCAM-1 and ICAM-1 surface expression (flow cytometry; ELISA from conditioned media); MCP-1 secretion (monocyte chemoattractant; ELISA); E-selectin surface expression (leukocyte rolling mediator; ELISA); and NF-κB p65 nuclear translocation (confocal immunofluorescence DAPI/p65 overlap ratio). The MC1R specificity of these endothelial effects is confirmed by BMS-470539 (MC1R-selective agonist showing similar protection) and by MC1R siRNA knockdown abrogating the PT-141 endothelial anti-inflammatory effect.

Monocyte adhesion to activated endothelial monolayers (THP-1 fluorescent dye CM-DiI 2µM labelled monocytes; adhesion to PT-141-pre-treated HUVEC monolayer for 15–30 minutes at 37°C; non-adherent cells removed by washing; fluorescence reading of adherent monocytes) provides a functional cardiovascular inflammatory endpoint directly relevant to atherosclerosis initiation and monocyte recruitment in plaque formation.

Atherosclerosis-Relevant Research: Foam Cell Biology and Plaque Macrophage

Foam cell formation — the accumulation of cholesterol esters in macrophages through scavenger receptor-mediated oxLDL uptake — is a central event in early atherosclerotic plaque development. MC1R on macrophages and foam cells modulates lipid handling through cAMP-ABCA1 upregulation (ABCA1 mediates reverse cholesterol transport by exporting cholesterol to apoA-I), NF-κB-dependent inflammatory cytokine suppression in foam cells, and autophagy-lysosomal cholesterol egress.

Foam cell research models use THP-1 human monocytes differentiated with PMA (100ng/mL, 48h) to macrophages, then treated with oxLDL (50–100µg/mL protein, 24–48h) in the presence or absence of PT-141 (10–100nM). Endpoints: Oil Red O staining (intracellular lipid; isopropanol extraction OD510nm); [³H]-oxLDL uptake (scintillation counting); ABCA1 mRNA qPCR and protein western (reverse cholesterol transport capacity); cAMP-PKA-CREB Ser-133 western (mechanistic PKA activation confirmation); and Luminex inflammatory cytokine panel from foam cell conditioned media (TNF-α, IL-6, MCP-1, IL-1β — all suppressed by MC1R-cAMP in foam cells).

In ApoE⁻/⁻ mice on Western diet (16 weeks), PT-141 treatment (s.c. 3×/week, 8 weeks) produces measurable differences in: aortic root lesion area (Oil Red O); plaque macrophage content (CD68 or MAC-2 IHC); collagen/SMC content (fibrous cap stability; α-SMA + Masson trichrome); necrotic core area; and inflammatory marker expression (NF-κB p65, VCAM-1, MCP-1 IHC in plaque). However, blood pressure elevation produced by systemic PT-141 may confound interpretation — requiring pair-wise hydralazine (vasodilator) BP normalisation in control arms to separate MC receptor-mediated anti-inflammatory effects from haemodynamic consequences of BP change.

Cardiac Fibrosis Research: MC Receptor Signalling in Cardiac Fibroblasts

Cardiac fibrosis — driven by TGF-β1-Smad2/3-mediated cardiac fibroblast activation, ECM collagen deposition, and myofibroblast (α-SMA+) transdifferentiation — is a major determinant of cardiac dysfunction in hypertension, post-MI remodelling, and HFpEF. MC1R expression in cardiac fibroblasts (detectable by RT-PCR in human cardiac fibroblast primary cultures and rat neonatal cardiac fibroblasts NRCF) provides a potential direct anti-fibrotic target for melanocortin signalling.

In TGF-β1 (5ng/mL, 48h)-stimulated primary cardiac fibroblasts or NRCF, PT-141 (10–100nM) pre-treatment modulates: α-SMA mRNA (qPCR) and protein (western blot — myofibroblast activation marker); COL1A1 and COL3A1 mRNA; Smad2/3 pS465/467 nuclear-to-cytoplasmic ratio by western on fractionated lysate; and Sircol-measurable secreted collagen in conditioned media. The MC1R-cAMP-PKA mechanism is predicted to reduce Smad2/3 phosphorylation through PKA-mediated inhibition of Smad linker region phosphorylation (Ser-206/Ser-210; Smad3) that prevents nuclear accumulation, providing a convergent anti-fibrotic mechanism parallel to GHK-Cu’s anti-fibrotic TGF-β1-Smad2/3 inhibition through NRF2-HO-1.

TAC (transverse aortic constriction) model of pressure-overload cardiac hypertrophy and fibrosis (26-gauge needle ligation; 4 weeks) in C57BL/6 mice provides in vivo cardiac fibrosis research context for PT-141. Echocardiographic M-mode LVEF, LVEDV, IVSd; Sirius Red collagen area% in LV histology; α-SMA IHC myofibroblast density; and BNP/NT-proBNP plasma ELISA constitute the fibrosis endpoint battery.

Sepsis-Related Cardiovascular Research: MC Anti-Inflammatory Cytoprotection

Septic cardiomyopathy — cardiac dysfunction complicating sepsis through inflammatory cytokine-mediated cardiomyocyte apoptosis, mitochondrial dysfunction, and calcium handling impairment — represents a cardiovascular research area where melanocortin anti-inflammatory biology is mechanistically relevant. LPS-induced cardiomyopathy in rodents (10mg/kg LPS i.p. in C57BL/6; echocardiography LVEF assessment at 6h, 12h, 24h) produces reproducible cardiac dysfunction with elevated troponin, reduced LVEF, and cardiac IL-6/TNF-α/IL-1β elevation.

Alpha-MSH and melanocortin agonists have established cytoprotective effects in LPS cardiac models through MC1R/MC3R-cAMP-NF-κB inhibition in cardiomyocytes and macrophages, reduced NLRP3-IL-1β inflammasome activation, and eNOS-NO preservation. PT-141 as an MC agonist in LPS cardiomyopathy uses the same mechanistic framework with the pharmacological advantage of peptide stability (cyclic structure; t½ >60 minutes in rodents versus <5 minutes for linear α-MSH) and oral bioavailability potential.

Experimental Design for PT-141 Cardiovascular Research

Critical controls for PT-141 cardiovascular research: HS024 or JKC-363 (MC4R antagonist) to dissect pressor/autonomic from anti-inflammatory effects; BMS-470539 (MC1R-selective) for endothelial/macrophage-specific effects; hydralazine or amlodipine BP correction in atherosclerosis models to prevent haemodynamic confounding; and agouti-related peptide (AgRP) as endogenous MC4R inverse agonist for pressor mechanism control. The cyclic structure of PT-141 confers protease resistance (t½ ~45–60 minutes in plasma versus <5 minutes for α-MSH), but standard purity verification (HPLC >98%, MS confirmation of 1,025 Da MW) remains essential.

The transient hypertension produced by systemic PT-141 administration (typically resolved within 2 hours at standard research doses) must be measured and reported in all cardiovascular studies to allow researchers to attribute observed cardiovascular endpoints to direct MC receptor pharmacology versus secondary haemodynamic consequences. Telemetric BP monitoring concurrent with all efficacy endpoint measurements is the methodological standard for PT-141 cardiovascular research.

Summary of Key Research Endpoints for PT-141 Cardiovascular Research

Core PT-141 cardiovascular endpoints include: DSI telemetry 24h MAP systolic diastolic HR locomotor, BRS sequence method Oxford phenylephrine dose-response ms/mmHg, HS024 JKC-363 MC4R antagonist prazosin α-blocker specificity controls, Langendorff LVDP HR CF RPP LDH TTC infarct%/in vivo LAD 30min troponin-I ELISA LVEF echo 24h Akt Ser-473-ERK-eNOS-GSK-3β RISK western cytochrome c caspase-3 NLRP3-ASC, TNF-α 10ng/mL HUVEC VCAM-1 ICAM-1 E-selectin flow ELISA MCP-1 NF-κB p65 confocal THP-1 CM-DiI adhesion MC1R siRNA BMS-470539 specificity, THP-1 PMA-macrophage oxLDL 50-100µg/mL Oil Red O [³H]-oxLDL ABCA1 mRNA western cAMP-PKA-CREB Ser-133 Luminex foam cell cytokine, ApoE⁻/⁻ WD 16w Oil Red O aortic root CD68 α-SMA Masson trichrome necrotic core NF-κB p65 VCAM-1 IHC hydralazine BP-normalisation confound control, TGF-β1 5ng/mL NRCF α-SMA COL1A1 Smad2/3 pS465/467 Sircol/TAC 26g echocardiography Sirius Red α-SMA BNP, LPS 10mg/kg LVEF 6/12/24h troponin cardiac IL-6-TNF-α-IL-1β NLRP3 cAMP-NF-κB cyclic structure t½ 45-60min telemetric BP concurrent all endpoints.